

**BMPR1A Antibody (N-term)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP2004F**

**Specification**

---

**BMPR1A Antibody (N-term) - Product Information**

Application	WB, FC,E
Primary Accession	<a href="#">P36894</a>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	1-30

**BMPR1A Antibody (N-term) - Additional Information**

**Gene ID** 657

**Other Names**

Bone morphogenetic protein receptor type-1A, BMP type-1A receptor, BMPR-1A, Activin receptor-like kinase 3, ALK-3, Serine/threonine-protein kinase receptor R5, SKR5, CD292, BMPR1A, ACVRLK3, ALK3

**Target/Specificity**

This BMPR1A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human BMPR1A.

**Dilution**

WB~~1:1000  
FC~~1:10~50

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

BMPR1A Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

**BMPR1A Antibody (N-term) - Protein Information**

**Name** BMPR1A

**Synonyms** ACVRLK3, ALK3

**Function** On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6. May promote the expression of HAMP, potentially via its interaction with BMP2 (By similarity).

#### Cellular Location

Cell membrane; Single-pass type I membrane protein. Cell surface  
{ECO:0000250|UniProtKB:P36895}

#### Tissue Location


Highly expressed in skeletal muscle.

### BMPR1A Antibody (N-term) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### BMPR1A Antibody (N-term) - Images



Western blot analysis of lysates from HeLa, K562, MCF-7 cell line, human liver, mouse liver tissue lysate(from left to right), using BMPR1A Antibody(A13)(Cat. #AP2004f). AP2004f was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysates at 35ug per lane.



Flow cytometric analysis of WiDr cells using BMPR1A Antibody (N-term) (bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

### **BMPR1A Antibody (N-term) - Background**

The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.

### **BMPR1A Antibody (N-term) - References**

Waite, K.A., et al., Hum. Mol. Genet. 12(6):679-684 (2003).  
Zhou, X.P., et al., Am. J. Hum. Genet. 69(4):704-711 (2001).  
Astrom, A.K., et al., Mamm. Genome 10(3):299-302 (1999).  
ten Dijke, P., et al., Oncogene 8(10):2879-2887 (1993).  
Ide, H., et al., Cytogenet. Cell Genet. 81 (3-4), 285-286 (1998) ( ): ( ).

### **BMPR1A Antibody (N-term) - Citations**

- [Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy.](#)